NEW YORK (GenomeWeb News) – Rosetta Genomics said after the close of the market on Thursday that it has netted proceeds of about $6 million from a direct offering, and that it has regained compliance on at least one of two Nasdaq listing requirements that it previously failed to meet.

It added that it believes it has regained compliance with the second listing requirement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.